CoChat
Sign Up
Cited by 298Hematopoietic Stem Cell TransplantationAcute Myeloid Leukemia ResearchBlood disorders and treatments

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis

Open access
Dakic, Aleksandar, Metcalf, Donald, Di Rago, Ladina, Mifsud, Sandra, Wu, Li, Nutt, Stephen L.·2005·The Journal of Experimental Medicine
DOI 10.1084/jem.20050075PMC PMC2213186
Open this paper in CoChat — free account

Abstract

Although the transcription factor PU.1 is essential for fetal lymphomyelopoiesis, we unexpectedly found that elimination of the gene in adult mice allowed disturbed hematopoiesis, dominated by granulocyte production. Impaired production of lymphocytes was evident in PU.1-deficient bone marrow (BM), but myelocytes and clonogenic granulocytic progenitors that are responsive to granulocyte colony-stimulating factor or interleukin-3 increased dramatically. No identifiable common lymphoid or myeloid progenitor populations were discernable by flow cytometry; however, clonogenic assays suggested an overall increased frequency of blast colony-forming cells and BM chimeras revealed existence of long-term self-renewing PU.1-deficient cells that required PU.1 for lymphoid, but not granulocyte, generation. PU.1 deletion in granulocyte-macrophage progenitors, but not in common myeloid progenitors, resulted in excess granulocyte production; this suggested specific roles of PU.1 at different stages of myeloid development. These findings emphasize the distinct nature of adult hematopoiesis and reveal that PU.1 regulates the specification of the multipotent lymphoid and myeloid compartments and restrains, rather than promotes, granulopoiesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20050075

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Conditional deletion of PU.1 in adult hematopoiesis. (A) The genomic locus of PU.1. Exons are represented as boxes; introns are represented as black lines; coding regions are in gray; nontranslated regions are in white; arrows indicate the direction of translation. The alleles derived from the integration of the targeting vector and subsequent manipulations are shown. pA, polyadenylation signal sequence; circles, frt sites; triangles, loxP sites; stop, stop codons in all reading frames; splice acc., splice acceptor. Targeted PU.1 gfp alleles can be converted by flp-mediated deletion to PU.1 fl or Cre deletion to PU.1 Δ. The position and direction of the genotyping primers (a–e) and Eco RI sites are indicated. (B) Southern blot analysis of ES cell Eco RI-digested DNA showing the wild-type (6.6 kb) and targeted (5.3 kb) alleles (C) PCR genotyping of tail DNA using the primer set a/b/c showing the correct amplification of the wild-type, PU.1 gfp, and PU.1 fl alleles. (D) Flow cytometric analysis of E18.5 fetal liver from PU.1 Δ gfp/ + intercrosses showing loss of myeloid cells in the absence of PU.1 and the GFP fluorescence in progenitors (c-kit+). (E) PCR showing the relative polyIC-inducible deletion of the PU.1 fl allele in vivo. Mice were injected with polyIC on days 0 and 3 and analyzed on day 10. DNA was amplified with the primer combination b/c/d. (F) Western blot analysis of PU.1 of mice of the indicated genotypes. Equal loading was confirmed using β-actin. PU.1 is not expressed in most thymocytes and demonstrates nonspecific antibody binding. (G) GFP fluorescence in adult BM. PU.1 Δ gfp/ Δ gfp (gfp/gfp MxCre +) and control (gfp/+ MxCre −) mice are shown at 2 wk after polyIC injection.
Figure 1. Conditional deletion of PU.1 in adult hematopoiesis. (A) The genomic locus of PU.1. Exons are represented as boxes; introns are represented as black lines; coding regions are in gray; nontranslated regions are in white; arrows indicate the direction of translation. The alleles derived from the integration of the targeting vector and subsequent manipulations are shown. pA, polyadenylation signal sequence; circles, frt sites; triangles, loxP sites; stop, stop codons in all reading frames; splice acc., splice acceptor. Targeted PU.1 gfp alleles can be converted by flp-mediated deletion to PU.1 fl or Cre deletion to PU.1 Δ. The position and direction of the genotyping primers (a–e) and Eco RI sites are indicated. (B) Southern blot analysis of ES cell Eco RI-digested DNA showing the wild-type (6.6 kb) and targeted (5.3 kb) alleles (C) PCR genotyping of tail DNA using the primer set a/b/c showing the correct amplification of the wild-type, PU.1 gfp, and PU.1 fl alleles. (D) Flow cytometric analysis of E18.5 fetal liver from PU.1 Δ gfp/ + intercrosses showing loss of myeloid cells in the absence of PU.1 and the GFP fluorescence in progenitors (c-kit+). (E) PCR showing the relative polyIC-inducible deletion of the PU.1 fl allele in vivo. Mice were injected with polyIC on days 0 and 3 and analyzed on day 10. DNA was amplified with the primer combination b/c/d. (F) Western blot analysis of PU.1 of mice of the indicated genotypes. Equal loading was confirmed using β-actin. PU.1 is not expressed in most thymocytes and demonstrates nonspecific antibody binding. (G) GFP fluorescence in adult BM. PU.1 Δ gfp/ Δ gfp (gfp/gfp MxCre +) and control (gfp/+ MxCre −) mice are shown at 2 wk after polyIC injection.CC BY-NC-SA · PubMed Central
Figure 2. PU.1 inactivation results in relative expansion of granulopoiesis. Representative analysis of the (A) myeloid, (B) B lymphoid, and (C) erythroid lineages from the BM of PU.1 Δ / Δ (fl/fl MxCre +) and control (fl/fl MxCre -) mice. Mice were injected on days 0 and 3 with polyIC and analyzed after 2 or 8 wk. (D) PCR analysis showing the relative PU.1 deletion of total BM and sorted cells of the indicated lineages 2 wk after polyIC treatment. B cells were identified as CD19+B220+, granulocytes as Gr1+. PU.1 fl/Δ tail DNA was used as a control.
Figure 2. PU.1 inactivation results in relative expansion of granulopoiesis. Representative analysis of the (A) myeloid, (B) B lymphoid, and (C) erythroid lineages from the BM of PU.1 Δ / Δ (fl/fl MxCre +) and control (fl/fl MxCre -) mice. Mice were injected on days 0 and 3 with polyIC and analyzed after 2 or 8 wk. (D) PCR analysis showing the relative PU.1 deletion of total BM and sorted cells of the indicated lineages 2 wk after polyIC treatment. B cells were identified as CD19+B220+, granulocytes as Gr1+. PU.1 fl/Δ tail DNA was used as a control.CC BY-NC-SA · PubMed Central
Figure 3. Perturbed granulocytic differentiation in the absence of PU.1. (A) Histologic section of day 21 BM from mice of the indicated genotype. Insets show cytocentrifuge preparations of corresponding BM. (B) Histologic section of relatively mild and severe granulocytic infiltrations in the spleen at day 21. (C) Severe PU.1 Δ / Δ (fl/fl MxCre +) mice display splenomegaly and enhanced percentage of Gr-1+Mac-1− cells by flow cytometry. PCR showing efficient deletion of PU.1 fl and PU.1gfp alleles in 2-wk spleen of a PU.1 Δ / Δ gfp (fl/gfp MxCre +) mouse. Total, total splenocytes; Gr, Gr-1+ cells; B, CD19+B220+ B cells; T, CD3+ T cells; Er, CD71+Ter119+ nucleated erythrocytes. B cells also were gated on GFPhigh (BGhi) or GFPlow (BGlo). The fl and gfp alleles were amplified with the primer combination b/c/d and e/c/d, respectively. (D) Control (fl/fl MxCre -) and PU.1 Δ / Δ (fl/fl MxCre +) granulocytes were grown in G-CSF for 7 d before being analyzed by flow cytometry and morphology. PCR analysis showed the complete PU.1 deletion of cultured granulocytes. (E) BM Gr-1hi cells were sorted and analyzed by RT-PCR for the expression of granulocytic enzymes, myeloperoxidase (MPO), LF, and gp91.
Figure 3. Perturbed granulocytic differentiation in the absence of PU.1. (A) Histologic section of day 21 BM from mice of the indicated genotype. Insets show cytocentrifuge preparations of corresponding BM. (B) Histologic section of relatively mild and severe granulocytic infiltrations in the spleen at day 21. (C) Severe PU.1 Δ / Δ (fl/fl MxCre +) mice display splenomegaly and enhanced percentage of Gr-1+Mac-1− cells by flow cytometry. PCR showing efficient deletion of PU.1 fl and PU.1gfp alleles in 2-wk spleen of a PU.1 Δ / Δ gfp (fl/gfp MxCre +) mouse. Total, total splenocytes; Gr, Gr-1+ cells; B, CD19+B220+ B cells; T, CD3+ T cells; Er, CD71+Ter119+ nucleated erythrocytes. B cells also were gated on GFPhigh (BGhi) or GFPlow (BGlo). The fl and gfp alleles were amplified with the primer combination b/c/d and e/c/d, respectively. (D) Control (fl/fl MxCre -) and PU.1 Δ / Δ (fl/fl MxCre +) granulocytes were grown in G-CSF for 7 d before being analyzed by flow cytometry and morphology. PCR analysis showed the complete PU.1 deletion of cultured granulocytes. (E) BM Gr-1hi cells were sorted and analyzed by RT-PCR for the expression of granulocytic enzymes, myeloperoxidase (MPO), LF, and gp91.CC BY-NC-SA · PubMed Central
Figure 4. PU.1 is essential for multipotent lymphoid and myeloid progenitors. (A) BM lin− cells from 2-wk PU.1 Δ / Δ (fl/fl MxCre +) and control (fl/fl MxCre −) polyIC-treated mice were assayed for HSC and lymphoid and myeloid progenitors. For GFP analysis, PU.1 Δ gfp/ Δ (PU.1 gfp/flMxCre+) or control (PU.1 gfp/flMxCre-) mice were treated as above. (B) Cytocentrifuge preparation and cell cycle analysis of lin− cells. Inset: PCR showing complete deletion of exon-5 in lin− cells. Range of cycling cells (S+G2+M) observed from two experiments is indicated. (C) RT-PCR for key hematopoietic regulators and PU.1 target genes in lin− and total BM. HPRT was used as a control for cDNA input. −RT, no reverse transcriptase was used in the reaction. Samples were taken at four cycle intervals. Ikaros isoforms 1 and 2 are indicated.
Figure 4. PU.1 is essential for multipotent lymphoid and myeloid progenitors. (A) BM lin− cells from 2-wk PU.1 Δ / Δ (fl/fl MxCre +) and control (fl/fl MxCre −) polyIC-treated mice were assayed for HSC and lymphoid and myeloid progenitors. For GFP analysis, PU.1 Δ gfp/ Δ (PU.1 gfp/flMxCre+) or control (PU.1 gfp/flMxCre-) mice were treated as above. (B) Cytocentrifuge preparation and cell cycle analysis of lin− cells. Inset: PCR showing complete deletion of exon-5 in lin− cells. Range of cycling cells (S+G2+M) observed from two experiments is indicated. (C) RT-PCR for key hematopoietic regulators and PU.1 target genes in lin− and total BM. HPRT was used as a control for cDNA input. −RT, no reverse transcriptase was used in the reaction. Samples were taken at four cycle intervals. Ikaros isoforms 1 and 2 are indicated.CC BY-NC-SA · PubMed Central
Figure 5. PU.1 regulates granulocyte production from the GMP. BM lin− cells from 36-h post-polyIC treatment PU.1 Δ / Δ (fl/fl MxCre +) and control (fl/fl MxCre −) mice were assayed for erythromyeloid progenitors. Sorted CMP and GMP using the indicated gates were subjected to PCR for PU.1 exon-5 deletion. Cytocentrifuge preparations were stained with May-Grunwald-Giemsa. Sorted cells were cultured in the indicated cytokines for 7 d, stained, and counted. 100 cells were plated in quadruplicate for each stimulus. Numbers represent the mean ± average deviation from three independent experiments.
Figure 5. PU.1 regulates granulocyte production from the GMP. BM lin− cells from 36-h post-polyIC treatment PU.1 Δ / Δ (fl/fl MxCre +) and control (fl/fl MxCre −) mice were assayed for erythromyeloid progenitors. Sorted CMP and GMP using the indicated gates were subjected to PCR for PU.1 exon-5 deletion. Cytocentrifuge preparations were stained with May-Grunwald-Giemsa. Sorted cells were cultured in the indicated cytokines for 7 d, stained, and counted. 100 cells were plated in quadruplicate for each stimulus. Numbers represent the mean ± average deviation from three independent experiments.CC BY-NC-SA · PubMed Central
Figure 6. Competitive BM reconstitution. (A) PU.1 fl/fl MxCre+ BM was mixed with Ly5.1 BM (2:1 ratio) and used to reconstitute lethally irradiated Ly5.1 mice. The degree of reconstitution was assessed from peripheral blood after 6 wk, followed by the induction of PU.1 deletion by polyIC. Flow cytometric analysis of spleen from chimeric mice at 24 wk. Ly5.1− cells were almost entirely PU.1-deficient granulocytes (Gr-1+Mac-1−), whereas Ly5.1+ competitors were Gr-1+Mac-1+ (macrophages/granulocytes) and CD19+Ly5.2− (B cells). c-kit+CD71+ erythroid progenitors were present in both populations. (B) BM, thymus, spleen, and blood cells and sorted Ly5.1− and Ly5.1+ BM cells were subjected to PCR for PU.1 exon-5 deletion. PU.1 fl/Δ, PU.1 fl/+, and PU.1 + / Δ tail DNA was used as a control. (+) Competitor Ly5.1+ DNA. Note that the synthesis of + (WT) allele PCR product is more efficient that that of Δ allele and cannot be used for relative quantification of host/donor cellular contribution to chimerism. PU.1 Δ / Δ was amplified from the BM, whereas no PU.1-deleted cells were found in the thymus, spleen, or blood. (C) The percentage of PU.1 Δ / Δ cells in hematopoietic organs was determined at 6, 12, and 24 wk after polyIC injection. Total PU.1 Δ / Δ cells (Ly5.1−) are shown relative to Ly5.1+ cells. The numbers have been normalized for the predeletion reconstitution frequency. Because cells lose CD45 expression in some lineages, mutant cells were defined as Ter119−Ly5.1−.
Figure 6. Competitive BM reconstitution. (A) PU.1 fl/fl MxCre+ BM was mixed with Ly5.1 BM (2:1 ratio) and used to reconstitute lethally irradiated Ly5.1 mice. The degree of reconstitution was assessed from peripheral blood after 6 wk, followed by the induction of PU.1 deletion by polyIC. Flow cytometric analysis of spleen from chimeric mice at 24 wk. Ly5.1− cells were almost entirely PU.1-deficient granulocytes (Gr-1+Mac-1−), whereas Ly5.1+ competitors were Gr-1+Mac-1+ (macrophages/granulocytes) and CD19+Ly5.2− (B cells). c-kit+CD71+ erythroid progenitors were present in both populations. (B) BM, thymus, spleen, and blood cells and sorted Ly5.1− and Ly5.1+ BM cells were subjected to PCR for PU.1 exon-5 deletion. PU.1 fl/Δ, PU.1 fl/+, and PU.1 + / Δ tail DNA was used as a control. (+) Competitor Ly5.1+ DNA. Note that the synthesis of + (WT) allele PCR product is more efficient that that of Δ allele and cannot be used for relative quantification of host/donor cellular contribution to chimerism. PU.1 Δ / Δ was amplified from the BM, whereas no PU.1-deleted cells were found in the thymus, spleen, or blood. (C) The percentage of PU.1 Δ / Δ cells in hematopoietic organs was determined at 6, 12, and 24 wk after polyIC injection. Total PU.1 Δ / Δ cells (Ly5.1−) are shown relative to Ly5.1+ cells. The numbers have been normalized for the predeletion reconstitution frequency. Because cells lose CD45 expression in some lineages, mutant cells were defined as Ter119−Ly5.1−.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 5

  1. 2004, Blood., 104, 3437
  2. 1996, Curr. Top. Microbiol. Immunol., 211, 137
  3. 1995, Oncogene., 11, 1549
  4. 1995, Leukemia., 9, 1556
  5. 1992, Exp. Hematol., 20, 600

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Dakic, A., Metcalf, D., Di Rago, L., Mifsud, S., Wu, L., & Nutt, S. L.
Affiliations
  • Walter and Eliza Hall Institute of Medical Research (AU)
  • The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia
ORCID
Venue
The Journal of Experimental Medicine
Publisher
Rockefeller University Press
Published
2005-05-02
Volume
201
Issue
9
Pages
1487-1502
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
DOI
10.1084/jem.20050075
PMC
PMC2213186
OpenAlex
W2136610354
Cited by
297
References
51
Citations by year
2026: 4 · 2025: 4 · 2024: 15 · 2023: 13 · 2022: 6 · 2021: 9 · 2020: 7 · 2019: 12 · 2018: 13 · 2017: 17 · 2016: 9 · 2015: 18 · 2014: 15 · 2013: 26 · 2012: 21
FWCI
10.47
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
Funders
  • National Institutes of Health (CA22556)
  • Medical Research Council
  • National Health and Medical Research Council
  • Cancer Council Victoria
  • National Cancer Institute (R37CA022556, CA22556, R01CA022556)
Topics
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Hematology › Blood disorders and treatments
Keywords
PU.1, granulopoiesis, hematopoietic progenitor cells, CFU-GM, common myeloid progenitors, lymphocyte production, granulocyte colony-stimulating factor, interleukin-3, bone marrow chimeras, transcription factors, adult hematopoiesis
MeSH terms
Proto-Oncogene Protein Spi-1, Animals, Antibodies, Monoclonal, Blood Cell Count, Cell Differentiation, Cells, Cultured, Colony-Forming Units Assay, Flow Cytometry, Genetic Vectors, Genotype, Granulocytes, Hematopoietic Stem Cells, Mice, Inbred C57BL, Mice, Transgenic, Proto-Oncogene Proteins, Blotting, Western, Trans-Activators, DNA Primers, Reverse Transcriptase Polymerase Chain Reaction, Myeloid Cells, Green Fluorescent Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review